Hints and tips:
Related Special Reports
Related Topics
...The Department of Health and Social Care said NHS England and Novartis “continue to work closely together to roll out this treatment to those who need it”....
...Shares in GSK have fallen 5 per cent in the past five years, while many of its European rivals including Novo Nordisk, AstraZeneca and Novartis have soared....
...Novartis notched a 10 per cent increase in sales in 2023 as strong performance for its heart and arthritis medicines helped Europe’s second-largest pharmaceuticals company beat its guidance for the year....
...Where doubts creep in is how Novartis will replace lost sales from 2027....
...The pharmaceutical industry is close to agreeing a deal with the UK government over drug pricing, according to the chief financial officer of Swiss drugmaker Novartis....
...The results focus on the remaining business, focused on innovative drugs, after Novartis spun out its generics division Sandoz this month....
...Novartis already has a radioligand therapy drug for prostate cancer called Pluvicto on the market....
...focused Novartis”....
...Big share price moves in Europe this morning include Swiss pharmaceutical group Novartis, London-listed betting group Entain and French maker of rail infrastructure Alstom....
...Swiss pharmaceutical giant Novartis has launched a $15bn share buyback programme after raising its outlook for the year on the back of strong sales....
...Swiss drug maker Novartis is “fully on track” for the spinoff of generics division Sandoz in “early October”, pending shareholder approval in September, chief financial officer Harry Kirsch told reporters...
...Shares in Novartis were up just over 3 per cent in early trading on Tuesday, but have languished this year....
...The crunchy acronym was coined by Goldman Sachs for pharma companies GSK and Roche, Dutch chip company ASML, Switzerland’s Nestlé and Novartis, Danish drugmaker Novo Nordisk, France’s L’Oréal and LVMH, the...
...Novartis was evaluating its legal options but had not yet filed a lawsuit, he said....
...Novartis would pay $37.5mn upfront with an additional $1.2bn in performance-based incentives....
...The deal comes as pharmaceutical companies gather in San Francisco for an annual industry conference, with GSK rivals Johnson & Johnson, Novartis and Merck announcing acquisitions on Monday....
...Swiss drugmaker Novartis has told the UK drugs regulator some batches of a medicine given to kidney transplant patients may contain small glass shards....
...The chief executive of Swiss drugmaker Novartis has criticised EU compulsory licensing proposals, saying they will “erode investment” in the region in the medium to long-term....
...Alcon: The eyecare company, previously a part of Switzerland’s Novartis, lost 5.2 per cent after its third-quarter earnings slightly missed expectations and it narrowed its yearly forecast....
...Novartis chief executive Vas Narasimhan said in 2021 that he believed the radioligand market could be worth up to $10bn....
...Sanofi trades on a forward price/earnings ratio of 11 times, Roche on 12.4 times and Novartis on 14.5 times. By comparison, obesity drugs developer Novo Nordisk trades on 33.6 times....
...Novartis recently said it would spin off its generic drugmaking business Sandoz....
...pharmaceutical companies are gathered in San Francisco for an annual industry conference this week, with GSK rivals Johnson & Johnson striking a $2bn deal to acquire an oncology biotech, and Merck and Novartis...
...Novartis: Shareholders in the Swiss drugmaker will vote on whether to spin off its Sandoz generics business, valued at up to $25bn....
...This is aided by the fact that groups such as Novartis are based in the city, soon to be joined by AstraZeneca....
International Edition